Patent · US Active

Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)

US8883983B2 · kind B2 · utility

11Cited by

31References

30Claims

0Family size

Assignee

AMGEN INC. · US

Inventors

Simon Mark Jackson · Redwood City, US
Nigel Pelham Clinton Walker · Burlingame, US
Derek E. Piper · Santa Clara, US
Wenyan Shen · Redwood City, US
Chadwick Terence King · North Vancouver, CA
Randal R. Ketchem · Snohomish, US
Christopher Mehlin · Seattle, US
Teresa Arazas Carabeo · New York, US

Key dates

Filing date	Apr 24, 2014
Grant date	Nov 11, 2014
Priority date	—
Expiry date	Apr 24, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.